KEYTRUDA® Boosts Survival in High-Risk Locally Advanced Cervical Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has announced the successful outcome of the Phase 3 KEYNOTE-A18 trial, also recognized as ENGOT-cx11 This trial…
Merck Unveils Clinical Trial Strategy for New HPV Vaccine and GARDASIL®9 Single-Dose Regimen
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, made a significant announcement today at the EUROGIN 2024 HPV Congress. The company revealed its intentions to…
Hansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovative pharmaceutical company in China, and Biotheus Inc. (Biotheus), a clinical-stage biotech company specializing in biologics for oncology and inflammatory…
Update Consultation by WHO Experts: Revising Toxic Equivalency Factors for Dioxin-like Compounds and Selected Polychlorinated Biphenyls
In Lisbon, Portugal, the World Health Organization (WHO) recently hosted an expert panel to reassess the Toxic Equivalency Factors (TEFs) for chlorinated dioxin-like compounds, initially established in 2005. Background: Since…
Neurological Conditions Impact Over 1 in 3 Individuals, Ranking as the Primary Cause of Global Illness and Disability
A recent comprehensive study, published in The Lancet Neurology, has revealed staggering figures regarding neurological conditions worldwide. In 2021, over 3 billion individuals were found to be living with such…
WHO and UNICEF Introduce Complimentary Online Course on Children’s Environmental Health
Amidst the escalating challenges posed by environmental pollution and climate change, the World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF) have joined forces to launch a new…
Gender Disparities Unveiled: The Core of the Worldwide Health and Care Work Crisis, According to WHO Report
The latest publication from the World Health Organization (WHO), titled “Equity in Health and Care: Gender Dynamics in Undervalued Health and Care Labor,” sheds light on how gender disparities within…
Ionis Reports Encouraging Findings from Phase 2 Trial of ION224, Showing Clinical Effectiveness in NASH/MASH Treatment
Ionis has unveiled encouraging outcomes from its Phase 2 investigation of ION224, a DGAT2 antisense inhibitor aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH), previously termed nonalcoholic steatohepatitis (NASH). The study,…
Lupin Receives Approval from U.S. FDA for Doxycycline for Injection USP
Lupin Limited, a global pharmaceutical powerhouse, has secured approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application concerning Doxycycline for Injection USP,…
The Chemical Quality Control Laboratory: Guardian of Standards in the Pharmaceutical Plant
The Role of Quality Control at Orion Pharmaceuticals Maija Blomquist, the Quality Control Manager for Materials, Gels & Ointments, underscores the pivotal role of quality control in maintaining Orion’s product…
Optimizing Project Management for Pharmaceutical Manufacturing: A Roadmap to Effective Clinical Trials
Unlocking Project Management’s Role in CDMOs In the intricate web of pharmaceutical and biotech industries, Contract Development and Manufacturing Organizations (CDMOs) stand as pivotal partners, offering indispensable services like API…
Blueprint Medicines Unveils Inducement Grants in Accordance with Nasdaq Listing Rule 5635
Blueprint Medicines Corporation (Nasdaq: BPMC) has announced that as of March 1, 2024, the Compensation Committee of its Board of Directors has approved the granting of non-qualified stock options to…